Ocular Therapeutix, Inc (OCUL) stock
OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)
Close on Nov 17, 2026Market cap $1.32BP/E –Yield –
Ocular Therapeutix cash
Cash and short-term investments held at the end of each period.
Ocular Therapeutix's cash was $598.64M at Jun 30, 2026. For fiscal 2025 it was $737.06M, up 87.2% from the year before. Over ten years it grew 21.5% a year on average. The highest annual figure on record is $737.06M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $737.06M | +87.2% |
| FY2024 | Dec 31, 2024 | $393.72M | +101.1% |
| FY2023 | Dec 31, 2023 | $195.81M | +88.2% |
| FY2022 | Dec 31, 2022 | $104.06M | -37.3% |
| FY2021 | Dec 31, 2021 | $165.93M | -27.8% |
| FY2020 | Dec 31, 2020 | $229.82M | +308.9% |
| FY2019 | Dec 31, 2019 | $56.20M | -7.4% |
| FY2018 | Dec 31, 2018 | $60.68M | +46.1% |
| FY2017 | Dec 31, 2017 | $41.54M | -40.6% |
| FY2016 | Dec 31, 2016 | $69.87M | -33.6% |
| FY2015 | Dec 31, 2015 | $105.29M | +40.7% |
| FY2014 | Dec 31, 2014 | $74.83M | +327.5% |
| FY2013 | Dec 31, 2013 | $17.51M | -26.6% |
| FY2012 | Dec 31, 2012 | $23.85M | +347.5% |
| FY2011 | Dec 31, 2011 | $5.33M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $598.64M | +53.1% |
| Q1 FY2026 | Mar 31, 2026 | $666.70M | +90.7% |
| Q4 FY2025 | Dec 31, 2025 | $737.06M | +87.2% |
| Q3 FY2025 | Sep 30, 2025 | $344.77M | -19.3% |
| Q2 FY2025 | Jun 30, 2025 | $391.13M | -14.9% |
| Q1 FY2025 | Mar 31, 2025 | $349.68M | -27.6% |
| Q4 FY2024 | Dec 31, 2024 | $393.72M | +101.1% |
| Q3 FY2024 | Sep 30, 2024 | $427.22M | +286.4% |
| Q2 FY2024 | Jun 30, 2024 | $459.69M | +590.2% |
| Q1 FY2024 | Mar 31, 2024 | $482.89M | +511.0% |
| Q4 FY2023 | Dec 31, 2023 | $195.81M | +88.2% |
| Q3 FY2023 | Sep 30, 2023 | $110.55M | -8.6% |
| Q2 FY2023 | Jun 30, 2023 | $66.61M | -50.5% |
| Q1 FY2023 | Mar 31, 2023 | $79.03M | -45.7% |
| Q4 FY2022 | Dec 31, 2022 | $104.06M | -37.3% |
| Q3 FY2022 | Sep 30, 2022 | $120.95M | -32.5% |
| Q2 FY2022 | Jun 30, 2022 | $134.54M | -29.9% |
| Q1 FY2022 | Mar 31, 2022 | $145.42M | -30.5% |
| Q4 FY2021 | Dec 31, 2021 | $165.93M | -27.8% |
| Q3 FY2021 | Sep 30, 2021 | $179.28M | +153.8% |
| Q2 FY2021 | Jun 30, 2021 | $191.86M | +127.6% |
| Q1 FY2021 | Mar 31, 2021 | $209.38M | +334.8% |
| Q4 FY2020 | Dec 31, 2020 | $229.82M | +308.9% |
| Q3 FY2020 | Sep 30, 2020 | $70.64M | +8.0% |
| Q2 FY2020 | Jun 30, 2020 | $84.29M | +36.5% |
| Q1 FY2020 | Mar 31, 2020 | $48.15M | -36.9% |
| Q4 FY2019 | Dec 31, 2019 | $56.20M | -7.4% |
| Q3 FY2019 | Sep 30, 2019 | $65.41M | +15.0% |
| Q2 FY2019 | Jun 30, 2019 | $61.77M | +8.7% |
| Q1 FY2019 | Mar 31, 2019 | $76.25M | +21.2% |
| Q4 FY2018 | Dec 31, 2018 | $60.68M | +46.1% |
| Q3 FY2018 | Sep 30, 2018 | $56.86M | +11.1% |
| Q2 FY2018 | Jun 30, 2018 | $56.83M | -14.0% |
| Q1 FY2018 | Mar 31, 2018 | $62.91M | -21.7% |
| Q4 FY2017 | Dec 31, 2017 | $41.54M | -40.6% |
| Q3 FY2017 | Sep 30, 2017 | $51.17M | -32.5% |
| Q2 FY2017 | Jun 30, 2017 | $66.05M | – |
| Q1 FY2017 | Mar 31, 2017 | $80.38M | – |
| Q4 FY2016 | Dec 31, 2016 | $69.87M | – |
| Q3 FY2016 | Sep 30, 2016 | $75.75M | – |
See a number that looks wrong?